Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

被引：420

作者：

Bar-Or, Amit ^{[1
,2
]}

Calabresi, Peter A. J. ^{[3
]}

Arnlod, Douglas ^{[4
]}

Markowitz, Clyde ^{[5
]}

Shafer, Stuart ^{[6
]}

Kasper, Lloyd H. ^{[7
]}

Waubant, Ernmanuelle ^{[8
]}

Gazda, Suzanne ^{[9
]}

Fox, Robert J. ^{[10
]}

Panzara, Michael ^{[11
]}

Sarkar, Neena ^{[12
]}

Agarwal, Sunil ^{[12
]}

Smith, Craig H. ^{[12
]}

机构：

[1] McGill Univ, Montreal Neurol Inst, Expt Therapeut Program, Montreal, PQ H3A 2B4, Canada

[2] McGill Univ, Neuroimmunol Unit, Montreal, PQ H3A 2B4, Canada

[3] Johns Hopkins Univ Hosp, Dept Neurol, Baltimore, MD 21287 USA

[4] NeuroRx Res, Montreal, PQ, Canada

[5] Hosp Univ Penn, Philadelphia, PA 19104 USA

[6] Vero Neurol, Vero Beach, FL USA

[7] Dartmouth Med Sch, Lebanon, NH USA

[8] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA

[9] Integra Clin Res, San Antonio, TX USA

[10] Cleveland Clin, Mellen Ctr Multiple Sclerosis, Cleveland, OH 44106 USA

[11] Biogen Idec, Cambridge, MA USA

[12] Genentech Inc, San Francisco, CA 94080 USA

来源：

ANNALS OF NEUROLOGY | 2008年 / 63卷 / 03期

关键词：

D O I：

10.1002/ana.21363

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We evaluated the safety, tolerability, pharmacodynamics, and activity of B-cell depletion with rituximab in patients with relapsing-remitting multiple sclerosis, receiving two courses of rituximab 6 months apart, and followed for a total of 72 weeks. No serious adverse events were noted; events were limited to mild-to-moderate infusion-associated events, which tended to decrease with subsequent infusions. Infections were also mild or moderate, and none led to withdrawal. Fewer new gadolinium-enhancing or T2 lesions were seen starting from week 4 and through week 72. An apparent reduction in relapses was also observed over the 72 weeks compared with the year before therapy.

引用

页码：395 / 400

页数：6

共 27 条

[1] Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma [J].

Anderson, DR ;

GrilloLopez, A ;

Varns, C ;

Chambers, KS ;

Hanna, N .

BIOCHEMICAL SOCIETY TRANSACTIONS, 1997, 25 (02) :705-708

[2] Roles of immunoglobulins and B cells in multiple sclerosis: From pathogenesis to treatment [J].

Antel, Jack ;

Bar-Or, Amit .

JOURNAL OF NEUROIMMUNOLOGY, 2006, 180 (1-2) :3-8

[3] The immunology of multiple sclerosis [J].

Bar-Or, Amit .

SEMINARS IN NEUROLOGY, 2008, 28 (01) :29-45

[4] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets [J].

Clynes, RA ;

Towers, TL ;

Presta, LG ;

Ravetch, JV .

NATURE MEDICINE, 2000, 6 (04) :443-446

[5] Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks [J].

Cohen, Stanley B. ;

Emery, Paul ;

Greenwald, Maria W. ;

Dougados, Maxime ;

Furie, Richard A. ;

Genovese, Mark C. ;

Keystone, Edward C. ;

Loveless, James E. ;

Burmester, Gerd-Ruediger ;

Cravets, Matthew W. ;

Hessey, Eva W. ;

Shaw, Timothy ;

Totoritis, Mark C. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2793-2806

[6] B-cell differentiation in the CNS of patients with multiple sclerosis [J].

Corcione, A ;

Aloisi, F ;

Serafini, B ;

Capello, E ;

Mancardi, GL ;

Pistoia, V ;

Uccelli, A .

AUTOIMMUNITY REVIEWS, 2005, 4 (08) :549-554

[7] B cells and antibodies in CNS demyelinating disease [J].

Cross, AH ;

Trotter, JL ;

Lyons, JA .

JOURNAL OF NEUROIMMUNOLOGY, 2001, 112 (1-2) :1-14

[8] Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients [J].

Cross, Anne H. ;

Stark, Jennifer L. ;

Lauber, Joanne ;

Ramsbottom, Michael J. ;

Lyons, Jeri-Anne .

JOURNAL OF NEUROIMMUNOLOGY, 2006, 180 (1-2) :63-70

[9]

Duddy M, 2006, Int MS J, V13, P84

[10] Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis [J].

Duddy, Martin ;

Niino, Masaaki ;

Adatia, Femina ;

Hebert, Sherry ;

Freedman, Mark ;

Atkins, Harry ;

Kim, Ho Jin ;

Bar-Or, Amit .

JOURNAL OF IMMUNOLOGY, 2007, 178 (10) :6092-6099

← 1 2 3 →